Whereas miR-155 downregulates SHIP expression increasing PI3K-AKT signaling, a novel SHIP1 activator, AQX-435, reduced AKT phosphorylation and growth of DLBCL in vivo and cooperated with ibrutinib for tumor growth inhibition [376]. The gene discussed is AKT1; the disease is diffuse large B-cell lymphoma.